Concepedia

Mirat Shah

MS

Statistics

Publications

14

Citations

960

H-Index

12

Active since

2011

Affiliations

Center for Drug Evaluation and Research(Current)

United States Food and Drug Administration

Sidney Kimmel Comprehensive Cancer Center

Center for Devices and Radiological Health

Johns Hopkins University

Mirat Shah is an author at Center for Drug Evaluation and Research specializing in oncology, medicine, and pharmacology.

ORCID

Publications per year

2011–2025

14

Publications

14

The Drug-Dosing Conundrum in Oncology — When Less Is More

Mirat Shah, Atiqur Rahman, Marc R. Theoret et al. · New England Journal of Medicine · 2021 · 278 citations

, , +17

CDK4/6 Inhibitors: Game Changers in the Management of Hormone Receptor–Positive Advanced Breast Cancer?

Mirat Shah, Maria Raquel Nunes, Vered Stearns · PubMed · 2018 · 132 citations

, , +17

FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer

Asma Dilawari, Mirat Shah, Gwynn Ison et al. · Clinical Cancer Research · 2023 · 105 citations · Full text

, , +11

FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer

Mirat Shah, Christy Osgood, Anup Amatya et al. · Clinical Cancer Research · 2022 · 95 citations · Full text

, , +15

FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast Cancer

Mirat Shah, Suparna Wedam, Joyce Cheng et al. · Clinical Cancer Research · 2020 · 62 citations · Full text

, , +15

1–5 of 14